News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MaxCyte, Inc.® VLX™ and STX™ Transient Transfection Systems Are Acquired by Paragon Bioservices for Use in Vaccine and Protein Manufacturing


1/29/2013 9:45:31 AM

GAITHERSBURG, Md.--(BUSINESS WIRE)--MaxCyte, Inc., the pioneer in scalable, high performance transient transfection systems, is pleased to announce that Paragon Bioservices has acquired both the MaxCyte VLX® Large Scale Transfection System and the MaxCyte STX® Scalable Transfection System for use in contract manufacturing of recombinant proteins, antibodies, viral vectors, vaccines, and VLPs. The initial application of MaxCyte STX and VLX systems will be in fulfillment of a Department of Defense contract for the process development and manufacturing scale-up of VLP-type vaccines against Ebola Zaire, Ebola Sudan, and Marburg viruses in support of the ongoing preclinical evaluation of the efficacy, potency, and safety of these Filovirus vaccine candidates.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES